NCT06662006View on ClinicalTrials.gov

Nal-IRI/5-FU/LV Chemotherapy Combined with PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT As Second-line Therapy in Metastatic Pancreatic Cancer Patients

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Advanced Metastatic Pancreatic Cancer
Interventions
DRUG

nal-IRI,5-fu,LV, benmelstobart, anlotinib

liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU)/leucovorin (LV) (nal-IRI/5-FU/LV) combined with benmelstobart and anlotinib ± SBRT

All Listed Sponsors
lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER

NCT06662006 - Nal-IRI/5-FU/LV Chemotherapy Combined with PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT As Second-line Therapy in Metastatic Pancreatic Cancer Patients | Biotech Hunter | Biotech Hunter